Literature DB >> 20961363

Potential of ceragenin CSA-13 and its mixture with pluronic F-127 as treatment of topical bacterial infections.

K Leszczyńska1, A Namiot, K Cruz, F J Byfield, E Won, G Mendez, W Sokołowski, P B Savage, R Bucki, P A Janmey.   

Abstract

AIMS: Ceragenin CSA-13 is a synthetic mimic of cationic antibacterial peptides, with facial amphiphilic morphology reproduced using a cholic acid scaffold. Previous data have shown that this molecule displays broad-spectrum antibacterial activity, which decreases in the presence of blood plasma. However, at higher concentrations, CSA-13 can cause lysis of erythrocytes. This study was designed to assess in vitro antibacterial and haemolytic activity of CSA-13 in the presence of pluronic F-127. METHODS AND
RESULTS: CSA-13 bactericidal activity against clinical strains of bacteria associated with topical infections and in an experimental setting relevant to their pathophysiological environment, such as various epithelial tissue fluids and the airway sputum of patients suffering from cystic fibrosis (CF), was evaluated using minimum inhibitory and minimum bactericidal concentration (MIC/MBC) measurements and bacterial killing assays. We found that in the presence of pluronic F-127, CSA-13 antibacterial activity was only slightly decreased, but CSA-13 haemolytic activity was significantly inhibited. CSA-13 exhibits bacterial killing activity against clinical isolates of Staphylococcus aureus, including methicillin-resistant strains, Pseudomonas aeruginosa present in CF sputa, and biofilms formed by different Gram (+) and Gram (-) bacteria. CSA-13 bactericidal action is partially compromised in the presence of plasma, but is maintained in ascites, cerebrospinal fluid, saliva, and bronchoalveolar lavage fluid. The synergistic action of CSA-13, determined by the use of a standard checkerboard assay, reveals an increase in CSA-13 antibacterial activity in the presence of host defence molecules such as the cathelicidin LL-37 peptide, lysozyme, lactoferrin and secretory phospholipase A (sPLA).
CONCLUSION: These results suggest that CSA-13 may be useful to prevent and treat topical infection. SIGNIFICANCE AND IMPACT OF THE STUDY: Combined application of CSA-13 with pluronic F-127 may be beneficial by reducing CSA-13 toxicity.
© 2010 The Authors. Journal of Applied Microbiology © 2010 The Society for Applied Microbiology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20961363      PMCID: PMC3386848          DOI: 10.1111/j.1365-2672.2010.04874.x

Source DB:  PubMed          Journal:  J Appl Microbiol        ISSN: 1364-5072            Impact factor:   3.772


  46 in total

1.  Topical antimicrobials in combination with admission screening and barrier precautions to control endemic methicillin-resistant Staphylococcus aureus in an Intensive Care Unit.

Authors:  Ian M Gould; Fiona M MacKenzie; Graeme MacLennan; Diane Pacitti; Emma J Watson; David W Noble
Journal:  Int J Antimicrob Agents       Date:  2007-03-06       Impact factor: 5.283

Review 2.  Bacterial and fungal biofilm infections.

Authors:  A Simon Lynch; Gregory T Robertson
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

3.  Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum.

Authors:  R Bucki; F J Byfield; P A Janmey
Journal:  Eur Respir J       Date:  2007-01-10       Impact factor: 16.671

4.  Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13.

Authors:  Robert Bucki; Dorota B Namiot; Zbigniew Namiot; Paul B Savage; Paul A Janmey
Journal:  J Antimicrob Chemother       Date:  2008-05-01       Impact factor: 5.790

5.  Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates.

Authors:  Elke Peeters; Hans J Nelis; Tom Coenye
Journal:  J Microbiol Methods       Date:  2007-11-21       Impact factor: 2.363

6.  Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.

Authors:  Judy N Chin; Ronald N Jones; Helio S Sader; Paul B Savage; Michael J Rybak
Journal:  J Antimicrob Chemother       Date:  2007-12-12       Impact factor: 5.790

7.  Penetration of a selected antibiotic and antiseptic into a biofilm formed on orthopedic steel implants.

Authors:  Marzenna Bartoszewicz; Anna Rygiel; Marek Krzemiński; Anna Przondo-Mordarska
Journal:  Ortop Traumatol Rehabil       Date:  2007 May-Jun

8.  Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum.

Authors:  Robert Bucki; Audra Goach Sostarecz; Fitzroy J Byfield; Paul B Savage; Paul A Janmey
Journal:  J Antimicrob Chemother       Date:  2007-06-21       Impact factor: 5.790

Review 9.  The bacterial envelope as a target for novel anti-MRSA antibiotics.

Authors:  Françoise Van Bambeke; Marie-Paule Mingeot-Leclercq; Marc J Struelens; Paul M Tulkens
Journal:  Trends Pharmacol Sci       Date:  2008-02-11       Impact factor: 14.819

10.  Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice.

Authors:  Katarzyna Leszczyńska; Andrzej Namiot; David E Fein; Qi Wen; Zbigniew Namiot; Paul B Savage; Scott Diamond; Paul A Janmey; Robert Bucki
Journal:  BMC Microbiol       Date:  2009-09-03       Impact factor: 3.605

View more
  21 in total

1.  N-terminally modified linear and branched spermine backbone dipeptidomimetics against planktonic and sessile methicillin-resistant Staphylococcus aureus.

Authors:  Rikeshwer Prasad Dewangan; Seema Joshi; Shalini Kumari; Hemlata Gautam; Mohammed Shahar Yar; Santosh Pasha
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

2.  Surfactants: Role in biofilm management and cellular behaviour.

Authors:  Steven L Percival; Dieter Mayer; Robert S Kirsner; Greg Schultz; Dot Weir; Sashwati Roy; Afsaneh Alavi; Marco Romanelli
Journal:  Int Wound J       Date:  2019-03-18       Impact factor: 3.315

Review 3.  Antimicrobial Peptide Mimics for Clinical Use: Does Size Matter?

Authors:  Johan Svenson; Natalia Molchanova; Christina I Schroeder
Journal:  Front Immunol       Date:  2022-05-26       Impact factor: 8.786

4.  Bactericidal Activity of Ceragenin CSA-13 in Cell Culture and in an Animal Model of Peritoneal Infection.

Authors:  Robert Bucki; Katarzyna Niemirowicz; Urszula Wnorowska; Fitzroy J Byfield; Ewelina Piktel; Marzena Wątek; Paul A Janmey; Paul B Savage
Journal:  Antimicrob Agents Chemother       Date:  2015-07-27       Impact factor: 5.191

5.  Antibacterial activity of the human host defence peptide LL-37 and selected synthetic cationic lipids against bacteria associated with oral and upper respiratory tract infections.

Authors:  Katarzyna Leszczynska; Dorota Namiot; Fitzroy J Byfield; Katrina Cruz; Malgorzata Zendzian-Piotrowska; David E Fein; Paul B Savage; Scott Diamond; Christopher A McCulloch; Paul A Janmey; Robert Bucki
Journal:  J Antimicrob Chemother       Date:  2012-11-07       Impact factor: 5.790

6.  Susceptibility of Pseudomonas aeruginosa Biofilm to Alpha-Helical Peptides: D-enantiomer of LL-37.

Authors:  Scott N Dean; Barney M Bishop; Monique L van Hoek
Journal:  Front Microbiol       Date:  2011-07-04       Impact factor: 5.640

7.  Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus.

Authors:  Scott N Dean; Barney M Bishop; Monique L van Hoek
Journal:  BMC Microbiol       Date:  2011-05-23       Impact factor: 3.605

8.  Bactericidal activity and biocompatibility of ceragenin-coated magnetic nanoparticles.

Authors:  Katarzyna Niemirowicz; Urszula Surel; Agnieszka Z Wilczewska; Joanna Mystkowska; Ewelina Piktel; Xiaobo Gu; Zbigniew Namiot; Alina Kułakowska; Paul B Savage; Robert Bucki
Journal:  J Nanobiotechnology       Date:  2015-05-01       Impact factor: 10.435

9.  Polyelectrolyte-mediated increase of biofilm mass formation.

Authors:  Robert Bucki; Katarzyna Niemirowicz; Urszula Wnorowska; Marzena Wątek; Fitzroy J Byfield; Katrina Cruz; Marta Wróblewska; Paul A Janmey
Journal:  BMC Microbiol       Date:  2015-06-06       Impact factor: 3.605

10.  In vitro bactericidal and bacteriolytic activity of ceragenin CSA-13 against planktonic cultures and biofilms of Streptococcus pneumoniae and other pathogenic streptococci.

Authors:  Miriam Moscoso; María Esteban-Torres; Margarita Menéndez; Ernesto García
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.